Bowman-Birk inhibitor concentrate reduces colon inflammation in mice with dextran sulfate sodium-induced ulcerative colitis.
Bowman-Birk inhibitor concentrate (BBIC) is a soybean extract enriched in the Bowman-Birk inhibitor, a protein protease inhibitor. The Bowman-Birk inhibitor can inhibit proteases released from inflammation mediating cells and suppress superoxide anion radical secretion from immunocytes. This study investigates the ability of Bowman-Birk inhibitor concentrate to inhibit colon inflammation in the dextran sulfate sodium model of ulcerative colitis, an inflammatory bowel disease. When compared to mice on a standard diet, mice given food supplemented with 0.5% BBIC during and after dextran sulfate sodium treatment showed suppression of three of four scored histopathological inflammation criteria (P < 0.01), total histopathological score (P < 0.01), a 15% lower mortality rate (P < 0.01), and a delayed onset of mortality. We conclude that dietary Bowman-Birk inhibitor concentrate can beneficially affect dextran sulfate sodium-treated mice and may be useful in the treatment of human inflammatory bowel diseases, particularly ulcerative colitis.
Ware
J H
JH
Department of Radiation Oncology, University of Pennsylvania School of Medicine, Philadelphia, USA.
Wan
X S
XS
Newberne
P
P
Kennedy
A R
AR
D000818:Animals; D003093:Colitis, Ulcerative / Q000139:chemically induced / Q000188:drug therapy*; D003106:Colon / Q000187:drug effects; D016264:Dextran Sulfate; D004195:Disease Models, Animal; D051379:Mice; D008815:Mice, Inbred Strains; D014358:Trypsin Inhibitor, Bowman-Birk Soybean / Q000494:pharmacology / Q000627:therapeutic use*; D014361:Trypsin Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*
D014358:Trypsin Inhibitor, Bowman-Birk Soybean; D014361:Trypsin Inhibitors; D016264:Dextran Sulfate